Table 1 Characteristics of the samples used for the Linkage-Disequilibrium SCore regression (LDSC) and GeNetic cOVariance Analyzer (GNOVA) analyses.

From: Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders

Trait/disorder

Author

Year

PMID

Consortium

Ancestry

N

Cases

Controls

Neff

2hGlu

Saxena et al.

2010

20081857

MAGIC

European

15,234

   

BMI

Pulit et al.

2019

30239722

GIANT

European

697,734

   

FPG

Lagou et al.

2021

33402679

MAGIC

European

140,595

   

FPI

Lagou et al.

2021

33402679

MAGIC

European

98,210

   

HbA1c

Wheeler et al.

2017

28898252

MAGIC

European

123,665

   

HOMA-IR

Dupuis et al.

2010

20081858

MAGIC

European

37,037

   

MetS

Lind

2019

31589552

 

European

291,107

59,677

231,430

189,772.64

Obesity

Watanabe et al.

2019

31427789

 

European

244,890

9805

235,085

37,649.69

T2DM

Mahajan et al.

2018

30297969

DIAGRAM

European

898,130

74,124

824,006

272,025.75

ADHD

Demontis et al.

2019

30478444

PGC

European

53,293

19,099

34,194

49,017.41

AD

Wightman et al.

2021

34493870

PGC

European

762,917

86,531

676,386

306,866.18

AN

Watson et al.

2019

31308545

PGC

European

72,517

16,992

55,525

52,041.91

ASD

Grove et al.

2019

30804558

PGC

European

46,350

18,381

27,969

44,366.62

BD

Mullins et al.

2021

34002096

PGC

European

413,466

41,917

371,549

150,669.89

OCD

OCGAS/IOCDF-GC

2018

28761083

OCGAS/IOCDF-GC

European

9725

2688

7037

7780.14

MDD

Wray et al./Howard et al.

2019

29700475/ 29662059

PGC

European

500,199

170,756

329,443

449,855.91

SCZ

Pardinas et al.

2018

29483656

PGC + CLOZUK

European

105,318

40,675

64,643

99,863.42

TS

Yu et al.

2019

30818990

PGC

European

14,307

4819

9488

12,783.30

  1. 2hGlu glucose levels 2 h after an oral glucose challenge, BMI body mass index, FPG fasting plasma glucose, FPI fasting plasma insulin, HbA1c glycated haemoglobin, HOMA-IR homeostatic model assessment for insulin resistance, MetS metabolic syndrome, T2DM type 2 diabetes mellitus, ADHD attention-deficit/hyperactivity disorder, AD Alzheimer’s disease, AN anorexia nervosa, ASD autism spectrum disorder, BD bipolar disorder, MDD major depressive disorder, OCD obsessive-compulsive disorder, SCZ schizophrenia, TS Tourette’s syndrome, N total sample size, Neff effective sample size [Neff = 4/(1/Cases +  1/Controls)].